Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

John T. Leith; Shaker A. Mousa; Aleck Hercbergs; Hung Yun Lin; Paul J. Davis

Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

John T. Leith, Shaker A. Mousa, Aleck Hercbergs, Hung Yun Lin, Paul J. Davis

Research output: Contribution to journal › Review article › peer-review

Abstract

Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T₄), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T₄ through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.

Original language	English
Pages (from-to)	37069-37075
Number of pages	7
Journal	Oncotarget
Volume	9
Issue number	97
Publication status	Published - Dec 1 2018

Keywords

AKT
Epithelial-mesenchymal transition (EMT)
Integrin open configuration
L-thyroxine (T)
STAT3

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{ed8ff2a5e578428f8b6c5ab546e32649,

title = "Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone",

abstract = "Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T4), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T4 through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.",

keywords = "AKT, Epithelial-mesenchymal transition (EMT), Integrin open configuration, L-thyroxine (T), STAT3",

author = "Leith, {John T.} and Mousa, {Shaker A.} and Aleck Hercbergs and Lin, {Hung Yun} and Davis, {Paul J.}",

note = "Publisher Copyright: {\textcopyright} 2018 Leith et al.",

year = "2018",

month = dec,

day = "1",

language = "English",

volume = "9",

pages = "37069--37075",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "97",

}

TY - JOUR

T1 - Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

AU - Leith, John T.

AU - Mousa, Shaker A.

AU - Hercbergs, Aleck

AU - Lin, Hung Yun

AU - Davis, Paul J.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T4), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T4 through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.

AB - Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T4), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T4 through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.

KW - AKT

KW - Epithelial-mesenchymal transition (EMT)

KW - Integrin open configuration

KW - L-thyroxine (T)

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=85058321734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058321734&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85058321734

SN - 1949-2553

VL - 9

SP - 37069

EP - 37075

JO - Oncotarget

JF - Oncotarget

IS - 97

ER -

Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this